Cognition Therapeutics Reports Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies Treatment

Cognition Therapeutics reports positive Phase 2 results for zervimesine in treating dementia with Lewy bodies (DLB). The SHIMMER study showed improvements in behavioral and motor symptoms, while the SHINE study demonstrated a 95% reduction in cognitive decline in Alzheimer's patients with low p-Tau217 levels. These findings offer hope for a once-daily oral treatment addressing DLB's diverse symptoms, and the company plans to continue researching zervimesine's potential impact on neurodegenerative disorders.

Cognition Therapeutics, Inc. (CGTX) has announced positive Phase 2 results for its drug candidate zervimesine (CT1812) in treating dementia with Lewy bodies (DLB). The company's SHIMMER study, presented by James E. Galvin, MD, MPH, during the Alzheimer's Association International Conference (AAIC), demonstrated significant improvements in behavioral and motor symptoms of DLB patients. The study, which enrolled 130 adults with mild-to-moderate DLB, randomized participants to daily oral doses of zervimesine (100 mg or 300 mg) or placebo for six months [2].

The SHIMMER study showed that zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms compared to placebo [3]. These results suggest that zervimesine has a broad neuroprotective mechanism, offering potential benefits for DLB patients.

Additionally, Cognition Therapeutics reported positive clinical and biomarker effects of zervimesine in the low p-tau217 population in Phase 2 Alzheimer’s disease study, known as SHINE. The SHINE study demonstrated a 95% reduction in cognitive decline in Alzheimer's patients with low p-Tau217 levels [3].

The findings from these studies offer hope for a once-daily oral treatment addressing DLB's diverse symptoms. Cognition Therapeutics plans to continue researching zervimesine's potential impact on neurodegenerative disorders, with a focus on DLB and other related conditions.

References:
[1] https://www.marketscreener.com/quote/stock/COGNITION-THERAPEUTICS-IN-127926318/news/Cognition-Therapeutics-Inc-Announces-Positive-Clinical-Data-from-Zervimesine-Phase-2-Study-in-Deme-50525294/
[2] https://www.biospace.com/press-releases/cognition-therapeutics-positive-clinical-data-from-zervimesine-ct1812-phase-2-study-in-dementia-with-lewy-bodies-dlb-will-be-presented-in-a-podium-presentation-at-aaic